58
Views
6
CrossRef citations to date
0
Altmetric
Review

Refining an Alzheimer’s vaccine to avoid an inflammatory response

, &
Pages 809-816 | Published online: 24 Nov 2005

Bibliography

  • CITRON M: Alzheimer's disease: treatments in discovery and development. Nat. Neurosci. (2002) 5(Suppl.):1055–1057.
  • DAVIS KL, SAMUELS SC: In: Pharmacological Management of Neurological and Psychiatric Disorders. Enna SJ, Coyle JT (Eds), McGraw-Hill, New York, USA (1998):267–316.
  • SELKOE D: Alzheimer's disease: genes, proteins, and therapy. PhysioL Rev. (2001) 81:741–766.
  • MCLAURIN J, YANG DS, YIP CM, FRASER PE: Modulating factors in amyloid-beta fibril formation. J. Struct. Biol. (2000) 130:259–270.
  • NASLUND J, HAROUTUNIAN V, MOHS R et al.: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 283:1571–1577.
  • TERRY RD, PECK A, DETERESA R, SCHECHTER R, HOROUPIAN DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann. Neurol (1981) 10:184–192.
  • BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 82:239–259.
  • DICKSON DW, CRYSTAL HA, BEVONA C, HONER W, VINCENT I, DAVIES P: Correlations of synaptic and pathological markers with cognition of the elderly. NeurobioL Aging (1995) 16:285–298.
  • MCLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. NeuroL (1999) 46:860–666.
  • KLEIN WL, KRAFFT GA, FINCH CE: Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. (2001) 24:219–224.
  • GONG Y, CHANG L, VIOLA KL et ed.:Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100:10417–10422.
  • WALSH DN, KLYUBIN I, FADEEVA JV et al.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 416:535–539.
  • SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
  • ••First report to show that immunisationwith A131–42 results in decreased plaque load in both prevention and treatment paradigms.
  • JANUS C, PEARSON J, MCLAURIN J et al.: Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
  • •Report that demonstrates that decreased amyloid due to immunisation is accompanied by enhanced behaviour.
  • MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
  • •Simultaneous report in a different mouse model that showed improved cognition.
  • BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid O-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916–919.
  • BACSKAI BJ, KAJDASZ ST, CHRISTIE RH et al.: Imaging of amyloid-13 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369–372.
  • WILCOCK DM, GORDON MN, UGEN KE et al.: Number of A0 inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. (2001) 20:731–736.
  • BACSKAI BJ, KAJDASZ ST, MCLELLAN ME et al.: Non-Fc-mediated mechanisms are involved in clearance of amyloid-0 in vivo by immunotherapy. J. Neurosci. (2002) 22:7873–7878.
  • DAS P, HOWARD V LOOSBROCK N et al.: Amyloid-0 immunization effectively reduces amyloid deposition in FcRy-/- knock-out mice. J. Neurosci. (2003) 23:8532–8538.
  • WILCOCK DM, DICARLO G, HENDERSON D et al.: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. (2003) 23:3745–3751.
  • DEMATTOS RB, BALES KR, CUMMINS DJ et al.: Peripheral anti-A(3 antibody alters CNS and plasma A0 clearance and decreases brain A0 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA (2001) 98:8850–8855.
  • SOLOMON B, KOPPEL R, HANAN E et al.: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer O-amyloid peptide. Proc. Natl Acad. Sci. USA (1996) 93:452–455.
  • SOLOMON B, KOPPEL R, FRANKEL D et al.: Disaggregation of Alzheimer O-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA (1997) 94:4109–4112.
  • FRENKEL D, SOLOMON B, BENT-JAR I: Modulation of Alzheimer's 0-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol (2000) 106:23–31.
  • MCLAURIN J, CECAL R, KIERSTEAD ME et al.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 8:1263–1269.
  • BARD F, BARBOUR R, CANNON C et al.: Epitope and isotype specificities of antibodies to 0-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA (2003) 100:2023–2028.
  • DODEL RC, HAMPEL H, DU Y: Immunotherapy for Alzheimer's disease. Lancet Neurol (2003) 2:215–220.
  • SENIOR K: Dosing in Phase II trial of Alzheimer's vaccine suspended. Lancet Neurol (2002) 1:3.
  • ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 61:46–54.
  • ••First indication that severe side effects werepresent in AN-1792 clinical trials.
  • NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat. Med. (2003) 9:448–452.
  • •Case report of the first patient that died after the vaccine trial, which shows the decreased extracellular plaque load.
  • FERRER I, BOADA ROVIRA M, SANCHEZ GUERRA ML, REY MJ, COSTA-JUSSA F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 14:11–20.
  • PFEIFER M, BONCRISTIANO S, BONDOLFI Let al.: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 298:1379.
  • ••First report to demonstrate possible sideeffects of passive immunisation, and points to the need to determine CAA load before pursuing this treatment strategy.
  • ODDO S, BILLINGS L, KESSIAK JP, CRIBBS DH, LAFERLA FM: A0 Immunotherapy leads to clearance of early but not late, hyperphosphorylated Tau aggregates via the proteasome. Neuron (2004) 43:321–332.
  • •First attempt to try to link All clearance with changes in tau pathology.
  • BAYER AJ, BULLOCK R, JONES RW et al.: Evaluation of the safety and immunogenicity of synthetic A042 (AN1792) in patients with AD. Neurology (2005) 64:94–100.
  • HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against 0-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547–554.
  • FURLAN R, BRAMBILLA E, SAN VITO F et al.: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain (2003) 126:285–291.
  • MASLIAH E, HANSEN L, ADAME A et al.: A0 vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Ann. Neurol (2005) 64:129–131.
  • •First report to demonstrate similar pathological benefits after AN-1792 vaccination in patients that did not exhibit encephalitis.
  • LOMBARDO JA, STERN EA, MCLELLAN ME et al.: Amyloid-0 antibody treatment leads to rapid 814 normalization of plaque-induced neuritic alterations. J. Neurosci. (2003) 23:10879–10883.
  • FOX NC, BLACK RS, GILMAN S et al.: Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurology (2005) (In Press).
  • GILMAN S, KOLLER M, BLACK RS et al.: Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurology (2005) (In Press).
  • WEINER HL, SELKOE DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 420:879–884.
  • GRUBECK-LOEBENSTEIN B, BLASKO I, MARX F, TRIEB K: Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. (2000) 23:114.
  • MONSONEGO A. ZOTA V, KARN A et al.: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer's disease. J. Clin. Invest. (2003) 112:415–422.
  • •Identification of an epitope that is associated with decreased amyloid load and no toxicity.
  • TRIEB K, RANSMAYR G, SGONC R, LASSMANN H, GRUBECK-LOEBENSTEIN B: APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging (1996) 17:541–547.
  • PRIDE MW, BLACK RS, HAGEN M et al.: Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). NeurobioL Aging (2004) 25:574.
  • SEUBERT P, LEE M, BARD F et al.: Characterization of the humoral response to AN1792 immunization in AD patients. Neurobiol Aging (2004) 25:588.
  • SPINNEY L: Update on Elan vaccine for Alzheimer's disease. Lancet Neurol (2004) 3:5.
  • SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. PathoL (2001) 159:439–447.
  • SIGURDSSON EM, KNUDSEN E, ASUNI A et al.: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-b derivatives. J. Neurosci. (2005) 24:6277–6282.
  • LEVERONE JF, SPOONER ET, LEHMAN HK, CLEMENTS JD, LEMERE CA: Abetal-15 is less immunogenic than Abetal-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. Vaccine (2003) 21:2197–2206.
  • AGADJANYAN MG, GHOCHIKYAN A. PETRUSHINA I et al.: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from 13-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide./ Immunol (2005) 174:1580–1586.
  • NEUROINFLAIVIMATION WORKING GROUP: Inflammation and Alzheimer's disease. NeurobioL Aging (2000) 21:383–421.
  • MONSONEGO A, IMITOLA J, ZOTA V,OIDA T, WEINER HL: Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Thl cells. J. Immunol (2003) 171:2216–2224.
  • LEMERE CA. MARON R, SPOONER ET et al.: Nasal Abeta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. (2000) 920:328–331.
  • WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. NeuroL (2000) 48:567–579.
  • CRIBBS DH, GHOCHIKYAN A, VASILEVKO Vet al.: Adjuvant-dependent modulation of Thl and Th2 responses to immunization with beta-amyloid. Int. Immunol (2003) 15:505–514.
  • PUAUX AL, MICHEL ML: New gene-based approaches for an AIDS vaccine. Comp. Immunol MicrobioL Infect. Dis. (2003) 26:357–372.
  • FINN 0J: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol (2003) 3:630–640.
  • ZHANG J, XU S, QIN J et al.: A novel recombinant adeno-associated virus vaccine reduces behavioural impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. NeurobioL Dis. (2003) 14:365–379.
  • BOWERS WJ, MASTRANGELO MA, STANLEY HA, CASEY AE, MILO LJ, FEDEROFF HJ: HSV amplicon-mediated Af3 vaccination in Tg2576 mice: differential antigen-specific immune responses. NeurobioL Aging (2005) 26:393–407.
  • GHOCHIKYAN A, VASILEVKO V, PETRUSHINA I et al.: Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur. j Immunol (2003) 33:3232–3241.
  • KIM HD, KONG FK, CAO Y et al.: Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid-13 protein and GM-CSF reduces amyloid load in the brain. Neurosci. Lett. (2004) 370:218–223.
  • QU B, ROSENBURG RN, LIPING L, BOYER PJ, JOHNSTON SA: Gene vaccination to bias the immune response to Amyloid-13 peptide as therapy for Alzheimer's disease. Arch NeuroL (2004) 61: 1859-1864.
  • SCHILTZ JG, SALZER, U, MOHAJERI MH et al.: Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. MoL Med. (2004) 82:706–714.
  • FRENKEL D, KATZ 0, SOLOMON B et al.: Immunization against Alzheimer's 13-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA (2000) 97:11455–11459.
  • RACKE MM, BOONE LI, HEPBURN DL et al.: Exacerbation of cerebral amyloid angiopathy-associated microhaemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-13. j Neurosci. (2005) 25:629–636.
  • DODEL RC, DU C, DEPBOYLU C et ell.:Intravenous immunoglobulins containing antibodies against 13-amyloid for the treatment of Alzheimer's disease./ NeuroL Neurosurg. Psychiatry (2004) 75:1472–1474.
  • •Potential for a safe, well-established protocol to be effective for the treatment of AD, and one that might act via multiple mechanisms.
  • RANGAN S, LIU R, BRUNE D et al.: Degradation of 0-amyloid by proteolytic antibody light chains. Biochemistry (2003) 42:14328–14334.

Websites

  • http://www.elan.com/ research_development/Alzheimers/ Elan Alzheimer's Research. Accessed 26 April 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.